Defining the prognosis of early stage chronic lymphocytic leukaemia patients

British Journal of Haematology

Volumn 156, Issue 4, 2012, Pages 499-507

  Pepper, Chris ^a   Majid, Aneela ^b   Lin, Thet Thet ^a   Hewamana, Saman ^a,c   Pratt, Guy ^d   Walewska, Renata ^b   Gesk, Stefan ^e   Siebert, Reiner ^e   Wagner, Simon ^b   Kennedy, Ben ^b   Miall, Fiona ^b   Davis, Zadie A ^f   Tracy, Ian ^f   Gardiner, Anne C ^f   Brennan, Paul ^a   Hills, Robert K ^a   Dyer, Martin J S ^b   Oscier, David ^f   Fegan, Chris ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

CD38; Chronic lymphocytic leukaemia; Immunoglobulin gene; Prognosis; Stage A disease

Indexed keywords

CD38 ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGE; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HUMAN; IGHV GENE; LYMPHOCYTE DOUBLING TIME; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TIME TO FIRST TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; TIME FACTORS; YOUNG ADULT; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84856260422     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08974.x     Document Type: Article

References (32)

1. Best, O.G., Gardiner, A.C., Davis, Z.A., Tracy, I., Ibbotson, R.E., Majid, A., Dyer, M.J. & Oscier, D.G. (2009) A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia, 23, 212-214.
2. Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M.T., Monconduit, M., Belabbes, S. & Gremy, F. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
3. Carney, D.A., Westerman, D.A., Tam, C.S., Milner, A., Prince, H.M., Kenealy, M., Wolf, M., Januszewicz, E.H., Ritchie, D., Came, N. & Seymour, J.F. (2010) Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia, 12, 2056-2062.
4. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230-239.
5. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez-Guillermo, A., Campo, E. & Montserrat, E. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine, 348, 1764-1775.
6. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 1840-1847.
7. Del Principe, M.I., Del Poeta, G., Buccisano, F., Maurillo, L., Venditti, A., Zucchetto, A., Marini, R., Niscola, P., Consalvo, M.A., Mazzone, C., Ottaviani, L., Panetta, P., Bruno, A., Bomben, R., Suppo, G., Degan, M., Gattei, V., de Fabritiis, P., Cantonetti, M., Lo Coco, F., Del Principe, D. & Amadori, S. (2006) Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 108, 853-861.
8. Delgado, J., Pratt, G., Phillips, N., Briones, J., Fegan, C., Nomdedeu, J., Pepper, C., Aventin, A., Ayats, R., Brunet, S., Martino, R., Valcarcel, D., Milligan, D. & Sierra, J. (2009) Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. British Journal of Haematology, 145, 801-805.
9. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine, 343, 1910-1916.
10. Gentile, M., Cutrona, G., Neri, A., Molica, S., Ferrarini, M. & Morabito, F. (2009) Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica, 94, 887-888.
11. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
12. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
13. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 1848-1854.
14. Hamblin, T.J., Orchard, J.A., Ibbotson, R.E., Davis, Z., Thomas, P.W., Stevenson, F.K. & Oscier, D.G. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood, 99, 1023-1029.
15. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Journal of Clinical Oncology, 17, 3835-3849.
16. Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Dohner, H. & Stilgenbauer, S. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, 1410-1416.
17. Krober, A., Bloehdorn, J., Hafner, S., Buhler, A., Seiler, T., Kienle, D., Winkler, D., Bangerter, M., Schlenk, R.F., Benner, A., Lichter, P., Dohner, H. & Stilgenbauer, S. (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 969-975.
18. Molica, S. & Levato, D. (2001) What is changing in the natural history of chronic lymphocytic leukemia? Haematologica, 86, 8-12.
19. Molica, S., Mauro, F.R., Callea, V., Giannarelli, D., Lauria, F., Rotoli, B., Cortelezzi, A., Liso, V. & Foa, R. (2010) The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica, 95, 464-469.
20. Orchard, J.A., Ibbotson, R.E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P.W., Hamblin, T.J., Staudt, L.M. & Oscier, D.G. (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet, 363, 105-111.
21. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. & Pasternack, B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-234.
22. Rassenti, L.Z., Huynh, L., Toy, T.L., Chen, L., Keating, M.J., Gribben, J.G., Neuberg, D.S., Flinn, I.W., Rai, K.R., Byrd, J.C., Kay, N.E., Greaves, A., Weiss, A. & Kipps, T.J. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine, 351, 893-901.
23. Rassenti, L.Z., Jain, S., Keating, M.J., Wierda, W.G., Grever, M.R., Byrd, J.C., Kay, N.E., Brown, J.R., Gribben, J.G., Neuberg, D.S., He, F., Greaves, A.W., Rai, K.R. & Kipps, T.J. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood, 112, 1923-1930.
24. Shanafelt, T.D., Jenkins, G., Call, T.G., Zent, C.S., Slager, S., Bowen, D.A., Schwager, S., Hanson, C.A., Jelinek, D.F. & Kay, N.E. (2009) Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer, 115, 363-372.
25. Smith, MR, Neuberg, D, Flinn, IW, Grever, MR, Lazarus, HM, Rowe, JM, Dewald, G, Bennett, JM, Paietta, EM, Byrd, JC, Hussein, MA, Appelbaum, FR, Larson, RA, Litzow, MR & Tallman, MS (2011) Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood, 118, 3525-3527.
26. Smolej, L., Vroblova, V. & Novosad, J. (2008) Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease. International Journal of Laboratory Hematology, 30, 259-260; author reply 260.
27. Starczynski, J., Pepper, C., Pratt, G., Hooper, L., Thomas, A., Hoy, T., Milligan, D., Bentley, P. & Fegan, C. (2003) The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 123, 66-71.
28. Stilgenbauer, S., Sander, S., Bullinger, L., Benner, A., Leupolt, E., Winkler, D., Krober, A., Kienle, D., Lichter, P. & Dohner, H. (2007) Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica, 92, 1242-1245.
29. Tam, C.S., Shanafelt, T.D., Wierda, W.G., Abruzzo, L.V., Van Dyke, D.L., O'Brien, S., Ferrajoli, A., Lerner, S.A., Lynn, A., Kay, N.E. & Keating, M.J. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M D. Anderson and Mayo Clinic experience. Blood, 114, 957-964.
30. Wierda, W.G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., Beran, M., Giles, F., Ravandi, F., Lerner, S., Kantarjian, H. & Keating, M. (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 109, 4679-4685.
31. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H. & Stilgenbauer, S. (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood, 112, 3322-3329.
32. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. & Stilgenbauer, S. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.